Sumitomo Pharma Co., Ltd.
Notice Regarding Refinancing of Existing Borrowings through Bridge Loan
Sumitomo Pharma will execute a bridge loan refinancing of existing borrowings consisting of a term loan of 20 billion yen and a commitment line of 130 billion yen for the period from April 24, 2026 to April 23, 2027.
Key Figures
- Term Loan Contract Amount: 20 billion yen
- Commitment Line Contract Amount: 130 billion yen
- Outstanding Principal Balance of Existing Syndicated Loans: Term Loan 60 billion yen, Commitment Line 38.1 billion yen
AI要約
Overview of Refinancing
Sumitomo Pharma Co., Ltd. has decided, as of April 8, 2026, to refinance existing borrowings with a bridge loan for the purpose of wholly acquiring Myovant Sciences and forming a strategic partnership with Roivant Sciences. Concurrently with a new share issuance and secondary offering, existing borrowings guaranteed by Sumitomo Chemical Co., Ltd. will be fully repaid and replaced with the bridge loan without such guarantee. The borrowing amounts are 20 billion yen as a term loan and 130 billion yen as a commitment line, with the term from April 24, 2026 to April 23, 2027, and repayment in a lump-sum at maturity.
Details of Existing Borrowings and Future Outlook
The existing syndicated loan subject to repayment includes an outstanding balance of 60 billion yen out of 140 billion yen of term loan (Tranche A), and 38.1 billion yen out of 93 billion yen of commitment line (Tranche B). The existing loans were guaranteed by Sumitomo Chemical Co., Ltd. for the period from March 31, 2025 to March 31, 2028. Through this refinancing, the loans will be switched to a bridge loan without guarantees. The impact of this matter on consolidated results for the fiscal year ending March 2027 is expected to be minor.
